Literature DB >> 12438231

Antigen-specific CD4+ T-cell help is required to activate a memory CD8+ T cell to a fully functional tumor killer cell.

Feng Guang Gao1, Vithagna Khammanivong, Wen Jun Liu, Graham R Leggatt, Ian H Frazer, Germain J P Fernando.   

Abstract

Although the importance of CD4+ T-cell help for generation of an effective CD8+ effector cytotoxic T cell (CTL) response is well established, the role of T-cell help in the activation of memory T cells to become fully functional tumor killer cells is undefined. Using synthetic peptide immunizations corresponding to the major CTLs and T-helper epitopes of ovalbumin, adoptive transfers of ovalbumin-specific memory CTLs (mCTLs), and ovalbumin as the tumor-specific antigen in a mouse tumor model, we have determined that T help is essential for the activation of mCTLs to kill tumors. Our data show that T-helper cells specific for the tumor-associated antigen are required for the reactivation of mCTLs by antigen presented indirectly from tumor. In contrast, effector CTLs do not need T help to kill tumors. These results have implications for induction of tumor immunotherapy by immunization.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12438231

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  44 in total

Review 1.  The potential of CD4 T-cell memory.

Authors:  K Kai McKinstry; Tara M Strutt; Susan L Swain
Journal:  Immunology       Date:  2010-03-16       Impact factor: 7.397

Review 2.  Immunization delivered by lentiviral vectors for cancer and infectious diseases.

Authors:  Biliang Hu; April Tai; Pin Wang
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

3.  Single chain MHC I trimer-based DNA vaccines for protection against Listeria monocytogenes infection.

Authors:  Sojung Kim; Adam Zuiani; Javier A Carrero; Ted H Hansen
Journal:  Vaccine       Date:  2012-01-26       Impact factor: 3.641

4.  Processing of tumor antigen differentially impacts the development of helper and effector CD4+ T-cell responses.

Authors:  Dannie Bernard; Michael S Ventresca; Laura A Marshall; Carole Evelegh; Yonghong Wan; Jonathan L Bramson
Journal:  Mol Ther       Date:  2010-02-23       Impact factor: 11.454

5.  Tumor infiltrating T lymphocytes in colorectal cancer: Tumor-selective activation and cytotoxic activity in situ.

Authors:  Moritz Koch; Philipp Beckhove; Jan Op den Winkel; Daniel Autenrieth; Philipp Wagner; Daniel Nummer; Sebastian Specht; Dalibor Antolovic; Luis Galindo; Friedrich H Schmitz-Winnenthal; Volker Schirrmacher; Markus W Büchler; Jürgen Weitz
Journal:  Ann Surg       Date:  2006-12       Impact factor: 12.969

6.  Impaired T cell proliferation by ex vivo BET-inhibition impedes adoptive immunotherapy in a murine melanoma model.

Authors:  Jonathan Chee; Chelsea Wilson; Anthony Buzzai; Ben Wylie; Catherine A Forbes; Mitchell Booth; Nicola Principe; Bree Foley; Mark N Cruickshank; Jason Waithman
Journal:  Epigenetics       Date:  2019-08-26       Impact factor: 4.528

7.  Selective addition of CXCR3(+) CCR4(-) CD4(+) Th1 cells enhances generation of cytotoxic T cells by dendritic cells in vitro.

Authors:  Sung Hee Yoon; Sun Ok Yun; Jung Yong Park; Hee Yeun Won; Eun Kyung Kim; Hyun Jung Sohn; Hyun Il Cho; Tai Gyu Kim
Journal:  Exp Mol Med       Date:  2009-03-31       Impact factor: 8.718

8.  Role of interferon-γ and cytotoxic T lymphocytes in intraocular tumor rejection.

Authors:  Ann J Ligocki; Joseph R Brown; Jerry Y Niederkorn
Journal:  J Leukoc Biol       Date:  2015-11-17       Impact factor: 4.962

Review 9.  Adoptive immunotherapy of cancer using CD4(+) T cells.

Authors:  Pawel Muranski; Nicholas P Restifo
Journal:  Curr Opin Immunol       Date:  2009-03-13       Impact factor: 7.486

10.  Effect of B7.1 costimulation on T-cell based immunity against TAP-negative cancer can be facilitated by TAP1 expression.

Authors:  Xiao-Lin Li; Yong-Yu Liu; David Knight; Yoshinobu Odaka; J Michael Mathis; Runhua Shi; Jonathan Glass; Qian-Jin Zhang
Journal:  PLoS One       Date:  2009-07-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.